Torrent Pharma |
Domestic business disappoints – Maintain Hold |
HOLD
CMP: Rs 577 Target Price: Rs 618
n Q2’12 results were subdued - with Revenues at Rs6.6bn (up 19% YoY), EBITDA at Rs1.1bn (up 31%) & APAT at Rs793mn (up 15% YoY)
n Growth in revenues were led by 32% growth in exports – 57% growth in US, 28% growth in Heumann (German subsidiary) and 34% growth in Brazil
n Domestic business growth remained subdued at 7% on back of increased competition in gastro and anti-biotic segment
n We maintain our earnings estimates and target price of Rs618 (14x FY13 earnings of Rs44). Maintain Hold
Regards,
Deepak Malik |
Senior Research Analyst | Emkay Global Financial Services Ltd. | www.emkayglobal.com | Email : deepak...@emkayglobal.com |
Board No. : +91-22-66121212 | Extn. : 257 | DID : 66121257 | Mob : +91 9769811227 | |
|